Proteins that interact with 14-3-3 isoforms are involved in regulation of the cell cycle, intracellular trafficking/targeting, signal transduction, cytoskeletal structure and transcription. Recent novel roles for 14-3-3 isoforms include nuclear trafficking the direct interaction with cruciform DNA and with a number of receptors, small G-proteins and their regulators. Recent findings also show that the mechanism of interaction is also more complex than the initial finding of the novel phosphoserine/threonine motif. Non-phosphorylated binding motifs that can also be of high affinity may show a more isoform-dependent interaction and binding of a protein through two distinct binding motifs to a dimeric 14-3-3 may also be essential for full interaction. Phosphorylation of specific 14-3-3 isoforms can also regulate interactions. In many cases, they show a distinct preference for a particular isoform(s) of 14-3-3. A specific repertoire of dimer formation may influence which of the 14-3-3-interacting proteins could be brought together. Mammalian and yeast 14-3-3 isoforms show a preference for dimerization with specific partners in vivo.
Mammalian casein kinases I (CKI) belong to a family of serine/threonine protein kinases involved in diverse cellular processes including cell cycle progression, membrane trafficking, circadian rhythms, and Wnt signaling. Here we show that CKI␣ co-purifies with centaurin-␣ 1 in brain and that they interact in vitro and form a complex in cells. In addition, we show that the association is direct and occurs through the kinase domain of CKI within a loop comprising residues 217-233. These residues are well conserved in all members of the CKI family, and we show that centaurin-␣ 1 associates in vitro with all mammalian CKI isoforms. To date, CKI␣ represents the first protein partner identified for centaurin-␣ 1 . However, our data suggest that centaurin-␣ 1 is not a substrate for CKI␣ and has no effect on CKI␣ activity. Centaurin-␣ 1 has been identified as a phosphatidylinositol 3,4,5-trisphosphate-binding protein. Centaurin-␣ 1 contains a cysteine-rich domain that is shared by members of a newly identified family of ADPribosylation factor guanosine trisphosphatase-activating proteins. These proteins are involved in membrane trafficking and actin cytoskeleton rearrangement, thus supporting a role for CKI␣ in these biological events.
Casein kinase IK K (CKIK K) belongs to a family of serine/threonine protein kinases involved in membrane trafficking, RNA processing, mitotic spindle formation and cell cycle progression. In this report, we identified several CKIK K interacting proteins including RCC1, high mobility group proteins 1 and 2 (HMG1, HMG2), Erf, centaurin-K K 1 , synaptotagmin IX and CPI-17 that were isolated from brain as CKIK K co-purifying proteins. Actin, importin-K K 1 , importin-L L, PP2Ac, centaurin-K K 1 , and HMG1 were identified by affinity chromatography using a peptide column comprising residues 214^233 of CKIK K. We have previously shown that centaurin-K K 1 represents a CKIK K partner both in vitro and in vivo. The nuclear protein regulator of chromosome condensation 1 (RCC1) is a guanosine nucleotide exchange factor for Ran which is involved in nuclear transport and mitotic spindle formation. Here we show that CKIK K and RCC1 interact in brain and in cultured cells. However, the interaction does not involve residues 217^233 of CKIK K which are proposed from X-ray structures to represent an anchoring site for CKI partners. Formation of the RCC1/CKIK K complex is consistent with the association of the kinase with mitotic spindles. In conclusion, we have identified a number of novel CKIK K protein partners and their relations to CKI are discussed. ß
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.